Anika Therapeutics

Anika reported adjusted EPS of $0.27 for Q1 2026 (analysts: -$0.18) and revenue of $29.6m (+13% YoY), with both figures beating expectations. Gross margin rose to 64% (+800 basis points) and adjusted EBITDA climbed to $4.3m, while the company held $41m in cash and had no debt. Management reaffirmed its 2026 revenue guidance of $114–122.5m and expects growth in the commercial channel driven by Integrity and Hyalofast products. Risks include pricing pressure in the OEM business, regulatory uncertainty for Hyalofast (PMA) and Cingal (NDA), and the sustainability of the margin improvements. » Plus sur de.investing.com

Anika Therapeutics reported Q1 2026 revenue of $29.6 million (+13% year‑over‑year) and earnings per share of $0.27, substantially beating the consensus estimate of -$0.18. Gross margin improved to 64% (up 800 basis points) and adjusted EBITDA rose to $4.3 million. Despite the strong results, the stock fell 3.7% in premarket trading. The company reaffirmed its full‑year revenue guidance of $114–122.5 million and continues to cite pricing pressure in the OEM channel and ongoing FDA reviews as risks. » Plus sur de.investing.com

Anika presented its growth strategy at the CG Musculoskeletal Conference 2026, emphasizing expansion of its hyaluronic acid–based product portfolio, including Orthovisc, Monovisc, Cingal, Integrity and Hyalofast. The company is debt-free, holds more than $50 million in cash and reports a 17% CAGR in commercial sales over the past five years. For 2026 Anika forecasts revenue growth, with commercial-channel revenues expected to rise 10–20%; Hyalofast (PMA) and Cingal (NDA) are pending FDA approval. Integrity implant sales developed positively through 2025, while the OEM channel is expected to be stable to slightly down. » Plus sur de.investing.com